science

Pivekimab sunirine

Pivekimab sunirine is a science topic covered in the lgStudy science library. This page brings together a partial reference excerpt, illustrations, worked examples, real-world applications and a short study plan, so you can understand Pivekimab sunirine rather than just read about it. In short: Pivekimab sunirine, sold under the brand name Decnupaz, is an anti-cancer medication used for the treatment of blastic plasmacytoid dendritic cell neoplasm. It is a CD123-directed antibody and alkylating agent conjugate.

Key takeaways

Pivekimab sunirine belongs to science; place it in that map before memorising details.
Learn the definition first, then one example that makes the definition concrete.
Connect Pivekimab sunirine to a quantity you can measure, compute or draw — that is where exam questions come from.
Reproduce the core statement of Pivekimab sunirine from memory before moving on to harder problems.

Reference excerpt

Pivekimab sunirine, sold under the brand name Decnupaz, is an anti-cancer medication used for the treatment of blastic plasmacytoid dendritic cell neoplasm. It is a CD123-directed antibody and alkylating agent conjugate. It is given by intravenous injection. The most common side effects of pivekimab sunirine include swelling (edema), tiredness (fatigue), muscle and joint pain (musculoskeletal pain), bleeding (hemorrhage), infusion-related reactions, nausea, diarrhea, changes in kidney function tests (increased creatinine), low albumin levels, and changes in liver function tests (transaminases increased). Pivekimab sunirine was approved for medical use in the United States in May 2026.

Medical uses Pivekimab sunirine is indicated for the treatment of adults with blastic plasmacytoid dendritic cell neoplasm. Blastic plasmacytoid dendritic cell neoplasm is an ultra-rare and fast-growing cancer of the bone marrow and blood that can affect multiple organs, including the skin, lymph nodes, spleen, and liver.

Adverse effects The most common side effects of pivekimab sunirine include swelling (edema), tiredness (fatigue), muscle and joint pain (musculoskeletal pain), bleeding (hemorrhage), infusion-related reactions, nausea, diarrhea, changes in kidney function tests (increased creatinine), low albumin levels, and changes in liver function tests (transaminases increased). The US prescribing information includes a boxed warning for hepatotoxicity, including hepatic veno-occlusive disease, and warnings and precautions for infusion-related reactions, edema, sulfite allergic reactions, and embryo-fetal toxicity. Pivekimab sunirine may cause a severe form of liver damage (hepatotoxicity) called veno-occlusive disease (blockage of small blood vessels that makes it hard for blood to leave the liver, leading to backup and swelling), including severe or fatal hepatic veno-occlusive disease (also known as sinusoidal obstruction syndrome). Pivekimab sunirine may cause a serious side effect called infusion-related reaction, which may be life-threatening or lead to death if not treated. Pivekimab sunirine contains sulfite and may cause severe, life-threatening allergic reactions in some people. Pivekimab sunirine may cause severe fluid retention and harm to an unborn baby.

History Efficacy was evaluated in CADENZA (NCT03386513), a multi-center, open-label, single-arm clinical trial that included adult participants with treatment-naïve blastic plasmacytoid dendritic cell neoplasm (N=33) or relapsed or refractory blastic plasmacytoid dendritic cell neoplasm (N=51), without evidence of active central nervous system disease. Efficacy was based on the rate of complete remission or clinical complete remission. The trial included 116 adult participants with CD123-positive blood or bone marrow cancers, of whom 84 participants had blastic plasmacytoid dendritic cell neoplasm. There were 33 participants who had blastic plasmacytoid dendritic cell neoplasm that was never treated before, and 51 participants had blastic plasmacytoid dendritic cell neoplasm that either came back after previous treatment or did not get better with other treatment(s). The trial occurred at 18 locations in four countries: the United States, Italy, Spain, and France. The study included 73 participants in the United States. The benefits and side effects of pivekimab sunirine were evaluated in one open-label trial in adult participants with CD123-positive blood or bone marrow cancers. The efficacy of pivekimab sunirine was evaluated in 84 participants with blastic plasmacytoid dendritic cell neoplasm who received pivekimab sunirine intravenously (through a vein) once every three weeks until the disease worsened or participants experienced unacceptable side effects. The safety of pivekimab sunirine was evaluated in a pooled population of 116 participants who received the approved dose of pivekimab sunirine. This pooled safety population included the 84 participants with blastic plasmacytoid dendritic cell neoplasm as well as additional enrolled participants with other CD123-positive blood or bone marrow cancers treated at the approved dose.

Society and culture

Legal status Pivekimab sunirine was approved for medical use in the United States in May 2026. The US Food and Drug Administration granted the application for pivekimab sunirine priority review, breakthrough therapy, and orphan drug designations.

Names Pivekimab sunirine is the international nonproprietary name. Pivekimab sunirine is sold under the brand name Decnupaz.

References

Illustrations

Worked examples

Example 1 — a first encounter with Pivekimab sunirine

Start with the simplest possible case. Write down what Pivekimab sunirine claims or describes in one sentence, then invent the smallest concrete situation in which that sentence is true. In science, the smallest case is usually a single object, a single equation or a single measurement. Check that every symbol or term in your sentence has a meaning in that case.

Example 2 — changing one variable

Take the situation from Example 1 and change exactly one quantity: double it, halve it, or set it to zero. Predict what should happen to Pivekimab sunirine before you calculate. Comparing your prediction with the result is the fastest way to find out whether you understand the idea or only the words.

Example 3 — an exam-style question

Typical questions about Pivekimab sunirine ask you to (a) state it precisely, (b) apply it to given data, and (c) explain a limitation. Practise writing all three answers in under five minutes; the third part is what separates a full-mark answer from an average one.

Applications of Pivekimab sunirine

In research: Pivekimab sunirine appears in science research whenever the underlying quantities have to be modelled precisely. Papers usually cite it as a starting assumption and then explore where it breaks down.
In technology and industry: Engineering practice reuses Pivekimab sunirine in design rules, simulations and safety margins. Knowing the idea lets you read a specification sheet and understand why the numbers look the way they do.
In the classroom: Pivekimab sunirine is common in secondary-school and first-year university syllabi. It links to neighbouring topics Antibody–drug conjugate, Drugs not assigned an ATC code, Orphan drugs, so understanding it makes those chapters shorter.
In everyday life: Look for Pivekimab sunirine outside the textbook — in sport, cooking, traffic, electronics or the sky above you. An example you found yourself is remembered far longer than one you were given.

Ask Teacher Smith questions about this articleOpens your AI tutor with a question about “Pivekimab sunirine” →

Affiliate

Preply — study more efficiently by working with a personal tutor. 50% off.

How to study Pivekimab sunirine in 20 minutes

Read the reference excerpt below once, without taking notes.
Close the page and write down what Pivekimab sunirine means in your own words.
Compare your version with the excerpt and mark what you missed.
Work through the three examples above with pen and paper.
Explain Pivekimab sunirine out loud to somebody else — or to Teacher Smith in the lgStudy chat.

Frequently asked questions

What is Pivekimab sunirine in simple terms?

Why does Pivekimab sunirine matter?

Because it connects several science ideas at once: it gives you a definition you can apply, a quantity you can calculate, and a way to check whether a result is plausible.

How should I study Pivekimab sunirine?

Read the excerpt, restate it from memory, then work through the examples and applications listed on this page. The five-step study plan above takes about twenty minutes.

What does this page cover?

It gives you a compact reference excerpt plus original lgStudy explanations, examples, applications and study material on Pivekimab sunirine.